[Effect of aluminum hydroxide on serum calcium, serum phosphorus and calcium turnover in uremic patients].
D000141:Acidosis, Renal Tubular / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000535:Aluminum / Q000627:therapeutic use*; D001846:Bone Development / Q000187:drug effects; D001847:Bone Diseases / Q000188:drug therapy; D002118:Calcium / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D002127:Calcium Isotopes; D002908:Chronic Disease; D005260:Female; D006801:Humans; D006878:Hydroxides; D007444:Inulin / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000188:drug therapy; D010758:Phosphorus / Q000097:blood*; D011704:Pyelonephritis / Q000188:drug therapy; D013997:Time Factors; D014511:Uremia / Q000097:blood* / Q000150:complications / Q000188:drug therapy
D002127:Calcium Isotopes; D006878:Hydroxides; D010758:Phosphorus; D007444:Inulin; D000535:Aluminum; D002118:Calcium
Virkningen af aluminiumhydroksyd på serumcalcium og serumfosfor samt 47 calciumomsaetning hos uraemikere.